1. Scrip
  2. >>Therapy Areas
  3. >>Blood and Clotting

Jasper Data Show Potential Promise For Anti-CD117 Conditioning Agent

 
• By Alaric DeArment

Jasper announced data on the first three patients in the trial of briquilimab in sickle cell disease and beta-thalassemia patients, not long after another player, Magenta, announced a setback in its program.

Jasper announced early data for briquilimab, its CD117-directed monoclonal antibody • Source: Shutterstock

Jasper Therapeutics, Inc. made a significant achievement with positive early data on use of briquilimab as a conditioning agent for patients with sickle cell disease (SCD) and beta-thalassemia undergoing allogeneic stem cell transplant, especially after another company seeking to develop an alternative to the chemotherapy drugs traditionally used in the space, Magenta Therapeutics, Inc., announced a setback in its own program.

Jasper said on 3 January that the first three participants in an investigator-initiated Phase I/II study of briquilimab successfully engrafted...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

CSL Locks In Option To Buy VarmX In Blood Clotting Drug Bet

 
• By Manas Mishra

Deal Snapshot: CSL secures exclusive option to acquire VarmX, depending on results for a Phase III trial for its lead compound, VMX-C001, a reversal agent for Factor Xa inhibitors.

Third Sickle Cell Product From Pfizer’s Global Blood Buyout Hits Snag

 
• By Alaric DeArment

The drugmaker reported a negative Phase III study for inclacumab, after a partial clinical hold for osivelotor and pulling Oxbryta from the market.

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 
• By Alaric DeArment

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 
• By Alaric DeArment

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

More from Therapy Areas

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.

AstraZeneca’s Fasenra RESOLUTE Failure Highlights The Limits Of Biologics In COPD

 
• By Alexandra Shimmings

AstraZeneca’s IL-5 blocker has again missed in COPD, adding to a number of disappointments for biologics in this disease. Complex biology and overlapping inflammatory pathways seem to be at the heart of the problem.

Lilly’s Orforglipron Bests Novo Rival In First Oral Head-To-Head Study

 
• By Andrew McConaghie

The company’s cardiometabolic leader Ken Custer discusses the topline ACHIEVE-3 results in diabetes and just-published full results of ATTAIN-1 in obesity of orforglipron, with a pledge to maximize access to the oral GLP-1 therapy worldwide, once approved.